King Specialty Cardiovascular/Metabolics Force To Be In Place By September
This article was originally published in The Pink Sheet Daily
Executive Summary
Second quarter Altace sales up $10 mil. as Wyeth co-promotion winds down.
You may also be interested in...
Wyeth To Relinquish Altace Marketing To King At Year-End
Under a modified promotion agreement for the ACE inhibitor, King will take over sales and marketing of ramipril effective Jan. 1.
Depomed’s Glumetza Q3 Launch Will Be Executed By King
Commercialization agreement gives King rights to market extended-release metformin in the U.S., while Depomed retains co-promotion rights.
Novartis Institute For Tropical Diseases Could Have TB Drug In Clinic By Late 2007
Singapore-based institute is also looking at dengue fever and malaria, exec says in interview with “The Pink Sheet” DAILY.